Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy

Detalhes bibliográficos
Autor(a) principal: Marques, Vanessa Stuart
Data de Publicação: 2021
Outros Autores: Celesso, Jessica Ragazzi, Bicalho, Adriane Pimenta da Costa Val
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/19775
Resumo: Canine atopic dermatitis is an inflammatory and pruritic skin disease, with clinical characteristics associated with IgE antibodies, most commonly directed against environmental allergens which impact the quality of life in affected animals and their owners. Treatment is multifaceted and must be adapted to each patient individually. Currently, a medication based on caninized monoclonal antibody (mAb), called lokivetmab, has shown promise for controlling the signs of the disease, as it neutralizes interleukin IL-31, a cytokine that plays an important role in the pathogenesis of atopy. The impact of dermatological diseases in the life of the dog and its owner has only been studied in recent years through validated questionnaires. This additional measurement tool is important for evaluating the therapeutic success of interventions in atopic dermatitis, as clinical improvement may not correlate with an increased quality of life. This study aimed to evaluate the quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy. Ten atopic dogs treated at the dermatology service of the Veterinary Hospital of the Veterinary School from UFMG were selected. Quality of life was assessed using a validated questionnaire, before and after lokivetmab therapy. It concludes that treatment with lokivetmab significantly improved the quality of life of dogs with atopic dermatitis and their owners.
id UNIFEI_4ac41fc11663e837247672c0ee0f256a
oai_identifier_str oai:ojs.pkp.sfu.ca:article/19775
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapyEvaluación de la calidad de vida en perros con dermatitis atópica y sus tutores después del tratamiento con lokivetmabAvaliação da qualidade de vida em cães com dermatite atópica e seus tutores após terapia com lokivetmab Monoclonal antibodyAtopyCanineIL-31Questionnaire.Anticorpo monoclonalAtopiaCaninaIL-31Questionário.Anticuerpo monoclonalAtopiaCaninoIL-31Cuestionario.Canine atopic dermatitis is an inflammatory and pruritic skin disease, with clinical characteristics associated with IgE antibodies, most commonly directed against environmental allergens which impact the quality of life in affected animals and their owners. Treatment is multifaceted and must be adapted to each patient individually. Currently, a medication based on caninized monoclonal antibody (mAb), called lokivetmab, has shown promise for controlling the signs of the disease, as it neutralizes interleukin IL-31, a cytokine that plays an important role in the pathogenesis of atopy. The impact of dermatological diseases in the life of the dog and its owner has only been studied in recent years through validated questionnaires. This additional measurement tool is important for evaluating the therapeutic success of interventions in atopic dermatitis, as clinical improvement may not correlate with an increased quality of life. This study aimed to evaluate the quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy. Ten atopic dogs treated at the dermatology service of the Veterinary Hospital of the Veterinary School from UFMG were selected. Quality of life was assessed using a validated questionnaire, before and after lokivetmab therapy. It concludes that treatment with lokivetmab significantly improved the quality of life of dogs with atopic dermatitis and their owners.La dermatitis atópica canina es una enfermedad cutánea inflamatoria y pruriginosa, con características clínicas asociadas a los anticuerpos IgE, más comúnmente dirigidos contra alérgenos ambientales y que impacta en la calidad de vida de los animales afectados y sus guardianes. El tratamiento es multifacético y debe adaptarse a cada paciente. Actualmente, un medicamento basado en anticuerpos monoclonales caninizados (mAb), llamado lokivetmab, se ha mostrado prometedor para controlar los signos de la enfermedad, ya que neutraliza la interleucina (IL) -31, una citocina que desempeña un papel importante en la patogenia de la dermatitis atópica canina. El impacto de las enfermedades dermatológicas en la vida del perro afectado y sus tutores solo se ha estudiado en los últimos años, mediante cuestionarios validados. Se ha demostrado que esta herramienta de medición adicional es importante para evaluar el éxito terapéutico de las intervenciones en la dermatitis atópica, ya que la mejoría clínica puede no correlacionarse con una mejor calidad de vida. Este estudio tuvo como objetivo evaluar la calidad de vida de los perros con dermatitis atópica y sus tutores después de la terapia con lokivetmab. Se seleccionaron diez perros atópicos tratados en el servicio de dermatología del Hospital Veterinario de la Facultad de Veterinaria de la UFMG. Se evaluó la calidad de vida de los pacientes y sus tutores, mediante un cuestionario validado, antes y después del tratamiento con lokivetmab. Se puede concluir que el tratamiento con lokivetmab mejoró significativamente la calidad de vida de los perros con dermatitis atópica y sus guardianes.A dermatite atópica canina (DAC) é uma doença inflamatória e pruriginosa da pele, com características clínicas associadas aos anticorpos IgE, mais comumente direcionados contra alérgenos ambientais e que impacta na qualidade de vida (QV) dos animais acometidos e de seus tutores. O tratamento é multifacetado e deve ser adaptado a cada paciente. Atualmente, uma medicação baseada em anticorpo monoclonal (mAb) caninizado, denominada lokivetmab, tem se mostrado promissora para o controle dos sinais da doença, pois neutraliza a interleucina (IL)-31, citocina que desempenha papel importante na patogênese da DAC. O impacto das doenças dermatológicas na vida do cão afetado e de seus tutores tem sido estudado apenas nos últimos anos, por meio de questionários validados. Essa ferramenta de medição adicional tem se mostrado importante para a avaliação do sucesso terapêutico das intervenções na dermatite atópica, já que a melhora clínica pode não se correlacionar com o aumento da qualidade de vida. Este trabalho teve como objetivo avaliar a qualidade de vida de cães com dermatite atópica e seus tutores após terapia com lokivetmab. Foram selecionados 10 cães atópicos atendidos no serviço de dermatologia do Hospital Veterinário da Escola de Veterinária da UFMG. Os pacientes e seus tutores foram avaliados quanto a qualidade de vida, por meio de um questionário validado, antes e após terapia com lokivetmab. Pode-se concluir que o tratamento com lokivetmab melhorou de forma significativa a qualidade de vida dos cães com dermatite atópica e de seus tutores.Research, Society and Development2021-09-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1977510.33448/rsd-v10i11.19775Research, Society and Development; Vol. 10 No. 11; e392101119775Research, Society and Development; Vol. 10 Núm. 11; e392101119775Research, Society and Development; v. 10 n. 11; e3921011197752525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/19775/17650Copyright (c) 2021 Vanessa Stuart Marques; Jessica Ragazzi Celesso; Adriane Pimenta da Costa Val Bicalhohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMarques, Vanessa Stuart Celesso, Jessica Ragazzi Bicalho, Adriane Pimenta da Costa Val 2021-10-23T19:01:11Zoai:ojs.pkp.sfu.ca:article/19775Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:36.382304Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
Evaluación de la calidad de vida en perros con dermatitis atópica y sus tutores después del tratamiento con lokivetmab
Avaliação da qualidade de vida em cães com dermatite atópica e seus tutores após terapia com lokivetmab
title Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
spellingShingle Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
Marques, Vanessa Stuart
Monoclonal antibody
Atopy
Canine
IL-31
Questionnaire.
Anticorpo monoclonal
Atopia
Canina
IL-31
Questionário.
Anticuerpo monoclonal
Atopia
Canino
IL-31
Cuestionario.
title_short Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
title_full Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
title_fullStr Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
title_full_unstemmed Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
title_sort Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
author Marques, Vanessa Stuart
author_facet Marques, Vanessa Stuart
Celesso, Jessica Ragazzi
Bicalho, Adriane Pimenta da Costa Val
author_role author
author2 Celesso, Jessica Ragazzi
Bicalho, Adriane Pimenta da Costa Val
author2_role author
author
dc.contributor.author.fl_str_mv Marques, Vanessa Stuart
Celesso, Jessica Ragazzi
Bicalho, Adriane Pimenta da Costa Val
dc.subject.por.fl_str_mv Monoclonal antibody
Atopy
Canine
IL-31
Questionnaire.
Anticorpo monoclonal
Atopia
Canina
IL-31
Questionário.
Anticuerpo monoclonal
Atopia
Canino
IL-31
Cuestionario.
topic Monoclonal antibody
Atopy
Canine
IL-31
Questionnaire.
Anticorpo monoclonal
Atopia
Canina
IL-31
Questionário.
Anticuerpo monoclonal
Atopia
Canino
IL-31
Cuestionario.
description Canine atopic dermatitis is an inflammatory and pruritic skin disease, with clinical characteristics associated with IgE antibodies, most commonly directed against environmental allergens which impact the quality of life in affected animals and their owners. Treatment is multifaceted and must be adapted to each patient individually. Currently, a medication based on caninized monoclonal antibody (mAb), called lokivetmab, has shown promise for controlling the signs of the disease, as it neutralizes interleukin IL-31, a cytokine that plays an important role in the pathogenesis of atopy. The impact of dermatological diseases in the life of the dog and its owner has only been studied in recent years through validated questionnaires. This additional measurement tool is important for evaluating the therapeutic success of interventions in atopic dermatitis, as clinical improvement may not correlate with an increased quality of life. This study aimed to evaluate the quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy. Ten atopic dogs treated at the dermatology service of the Veterinary Hospital of the Veterinary School from UFMG were selected. Quality of life was assessed using a validated questionnaire, before and after lokivetmab therapy. It concludes that treatment with lokivetmab significantly improved the quality of life of dogs with atopic dermatitis and their owners.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-05
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/19775
10.33448/rsd-v10i11.19775
url https://rsdjournal.org/index.php/rsd/article/view/19775
identifier_str_mv 10.33448/rsd-v10i11.19775
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/19775/17650
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 11; e392101119775
Research, Society and Development; Vol. 10 Núm. 11; e392101119775
Research, Society and Development; v. 10 n. 11; e392101119775
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052808298496000

Registros relacionados